Reig Jofre submits results note on third quarter of 2021

REIG JOFRE’s revenues grew by 2% up to September 2021 with 4% growth in its EBITDA

Reig Jofre managed to increase its revenue figure through the recovery of prescription and consumer healthcare products, compared to 2020, when sales were driven by essential medicines linked to COVID-19 and disinfection products.

At the end of September, listed company REIG JOFRE achieved 173 million in sales, a 2% increase over the same period of the previous year. The lower level of antibiotic and OTC consumption, that may begin to reverse in the fourth quarter, holds steady. EBITDA grew by 4%, reaching €19.9 million, which results in profitability on sales consistent with previous periods exceeding 11%.

The Pharmaceutical Technologies division, focused on the sale of injectable and antibiotic products, had a decrease in its revenue, while there is already a clear recovery in the Specialty Pharmacare division, which is focused on prescription medical products, and in Consumer Healthcare, particularly in the FORTE PHARMA brand range in France and Benelux, its main markets.

Download the full document (PDF)